CD20+ Lymphoblastic Lymphoma
1 clinical trials · Condition
◉ Watch CD20+ Lymphoblastic Lymphoma
| Record | Firm | Date |
|---|---|---|
| Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (NCT02393157) | New York Medical College | 2015-08-21 |
Track CD20+ Lymphoblastic Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.